APA (7th ed.) Citation

SM, R., E, A., EK, A., H, Z., A, S., A, I., . . . DM, W. (2025). Optimized 5-HT2b inhibitors for neuropsychiatric syndromes with cognitive dysfunction. Alzheimer's & dementia (New York, N. Y.), 11(1), e70073. https://doi.org/10.1002/trc2.70073

Chicago Style (17th ed.) Citation

SM, Roy, Acquarone E, Argyrousi EK, Zhang H, Staniszewski A, Inoue A, Ziarek JJ, Arancio O, and Watterson DM. "Optimized 5-HT2b Inhibitors for Neuropsychiatric Syndromes with Cognitive Dysfunction." Alzheimer's & Dementia (New York, N. Y.) 11, no. 1 (2025): e70073. https://doi.org/10.1002/trc2.70073.

MLA (9th ed.) Citation

SM, Roy, et al. "Optimized 5-HT2b Inhibitors for Neuropsychiatric Syndromes with Cognitive Dysfunction." Alzheimer's & Dementia (New York, N. Y.), vol. 11, no. 1, 2025, p. e70073, https://doi.org/10.1002/trc2.70073.